Leathers S, et al. - In this retrospective analysis, researchers described the effectiveness, safety profile, and variables correlated with survival in patients with hepatocellular carcinoma (HCC) treated with sorafenib in South America. Between January 2010 and June 2017, HCC cases treated with sorafenib from 8 medical centers in 5 South American countries were analyzed. Due to side effects, patients who stopped sorafenib had shorter survival vs patients who were able to tolerate side effects and continue treatment. In a South American cohort, pretreatment elevation of platelets and advanced Barcelona Clinic Liver Cancer (BCLC) stage were independently related to poor survival on sorafenib.